Supernus Pharmaceuticals, Inc.: Attention Deficit Disorder with Hyperactivity trials
The registry lists 15 Attention Deficit Disorder with Hyperactivity studies with Supernus Pharmaceuticals, Inc. as lead sponsor. 1 are open to participants now and 12 have results posted.
Phase 1 1Phase 2 5Phase 3 7Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDRecruitingNCT04781140Phase 4
- Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsCompletedNCT06185985Phase 4Results posted
- Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDCompletedNCT04786990Phase 4Results posted
- Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedNCT04143217Phase 3Results posted
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedNCT04016779Phase 3Results posted
- Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDTerminatedNCT03638466Phase 2Results posted
- Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentTerminatedNCT03597503Phase 3Results posted
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)TerminatedNCT02691182Phase 3Results posted
- Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHDCompletedNCT02633527Phase 2Results posted
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)CompletedNCT02618434Phase 3Results posted
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)CompletedNCT02618408Phase 3Results posted
- Evaluation of Immediate-Release Viloxazine in Adults With ADHDCompletedNCT01107496Phase 1/2Results posted
- Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsCompletedNCT00626236Phase 2Results posted
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Active, not recruitingNCT02736656Phase 3
- A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01364662Phase 2